Therapeutic Asset Ratings

138 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
PEGASPARGASE Myelodysplastic Syndromes	Ciusss de L'Est de l'Île de Montréal	P3	BB (64)
Arsenic Trioxide Myelodysplastic Syndromes	The University of Hong Kong	P2/3	BB (64)
AMSACRINE Myelodysplastic Syndromes	Heinrich-Heine University, Duesseldorf	P3	B (63)
Rapamycin Myelodysplastic Syndromes	City of Hope Medical Center	P3	B (63)
PREDNISONE TABLETS Myelodysplastic Syndromes	Indiana University	P2	B (63)
Anti-Thymoglobulin, Rabbit Myelodysplastic Syndromes	The First Affiliated Hospital of Soochow University	P4	B (62)
ASPARAGINASE Myelodysplastic Syndromes	Children's Oncology Group	P3	B (62)
THIOGUANINE ANHYDROUS Myelodysplastic Syndromes	Children's Oncology Group	P3	B (62)
Benadryl Myelodysplastic Syndromes	M.D. Anderson Cancer Center	P2	B (62)
Hydroxyurea Myelodysplastic Syndromes	University Hospital Tuebingen	P3	B (60)
Orca-T Myelodysplastic Syndromes	Orca Biosystems, Inc.	P3	B (60)
Pevonedistat Myelodysplastic Syndromes	University of Leipzig	P3	B (60)
Venetoclax Myelodysplastic Syndromes	National Cancer Institute (NCI)	P3	B (60)
Bendamustine Myelodysplastic Syndromes	St. Petersburg State Pavlov Medical University	P2	B (60)
MERCAPTOPURINE ANHYDROUS Myelodysplastic Syndromes	Haukeland University Hospital	P2	B (60)
Mesna Myelodysplastic Syndromes	Center for International Blood and Marrow Transplant Research	P2	B (60)
ABATACEPT RECOMBINANT Myelodysplastic Syndromes	Center for International Blood and Marrow Transplant Research	P3	B (58)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Myelodysplastic Syndromes	Leland Metheny	P2	B (58)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Myelodysplastic Syndromes	David Wald	P2	B (58)
Allopurinol Myelodysplastic Syndromes	Masonic Cancer Center, University of Minnesota	P2	B (58)
Calcium folinate pentahydrate Myelodysplastic Syndromes	National Cancer Institute (NCI)	P2	B (58)
FENTANYL Myelodysplastic Syndromes	M.D. Anderson Cancer Center	P2	B (58)
Sorafenib Myelodysplastic Syndromes	St. Petersburg State Pavlov Medical University	P2	B (58)
Alpha-Interferon Myelodysplastic Syndromes	Peking University People's Hospital	P2	B (57)
ag-120 Myelodysplastic Syndromes	Ruijin Hospital	P2	B (56)

Showing 26 to 50 of 138 assets

PreviousPage 2 of 6Next